Study: Cryoablation puts a chill on ovarian cancer tumors February 29, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: cryoablation, femal reproductive system, late stage, ovarian cancer, treatment, tumors
add a comment
Study: Cryoablation puts a chill on ovarian cancer tumors
Cryoablation has been shown to be an effective form of treatment for ovarian cancer, and this “freeze and destroy” technique could offer an alternative to surgery or chemotherapy for patients whose disease is in the late stages and oligometastatic, according to research published in the Journal of Vascular and Interventional Radiology and presented at the 2012 International Symposium on Endovascular Therapy in Miami in January.
Hyun Bang, MD, of the department of radiology at Wayne State University School of Medicine in Detroit, and colleagues performed a study of 21 ovarian cancer patients who underwent ultrasound-guided, percutaneous cryoablation in order to assess complications, recurrences and overall survival. Forty-eight tumors on the soft tissue, liver and lungs were treated during the seven-year study period.
Results showed that the median survival was 56.9 months, though the authors noted an average period of 37.8 months occurred between the diagnosis of metastatic disease to the cryoablation procedure. For comparison, most women whose tumors aren’t successfully removed surgically—approximately 60 percent of cases—survive seven months to 30 months.
Bang and colleagues also calculated that cryoablation delivers results at a lower cost than alternative treatments. Medical costs in the study registered an average of $26,806 per life year saved compared with the current standard of care costing approximately $100,000 per life year saved.
“[Multisite cryoablation] of metastatic epithelial ovarian cancer is a well-tolerated treatment alternative, especially for patients with anesthesia risks, painful lesions or those seeking local control during chemotherapy,” concluded the authors. “Preliminary calculations of high patient survival and cost-effectiveness suggest that cryoablation could effectively and economically augment the palliative care of metastatic disease.”
Because cryoablation is performed using an extremely cold needle inserted into the skin, it causes less pain and offers a faster recovery than surgery, according to the authors.
The research team has published two papers detailing the findings as they relate to kidney and lung cancers, with a third recently submitted on colon cancer. Bang recognized the long-term effectiveness and financial benefits of the treatment in a statement, saying that with enough evidence and proven data, “eventually, people will start listening.”
Ovarian cancer is diagnosed in 22,000 women each year and is the most damaging cancer to the female reproductive system, according to the National Institutes of Health.
Tags: CA-125, chemotherapy, endometrial cancer, HIPEC, HITEC, malignant tumors malignant tissue, ovarian cancer, remission, surgery, treatment
add a comment
Targeted treatment for ovarian cancer to be studied at University Hospitals
Tuesday, February 28, 2012
CLEVELAND, Ohio — Physicians at University Hospitals Case Medical Center are developing four clinical trials to test a therapy that has been around for several decades, but which only recently has been used to treat ovarian, endometrial (uterine) and select other gynecologic cancers.
The studies, which physicians hope to begin this spring, have been designed for a very specific patient population — no more than a couple dozen women with ovarian or endometrial cancer will be enrolled in each one. The trials will help researchers compare and learn relatively quickly how to use heated intraperitoneal chemotherapy, or HIPEC, as effectively as possible, said Dr. Robert DeBernardo, a gynecologic oncologist at UH and assistant professor at Case Western Reserve University School of Medicine.
The procedure, administered in the operating room right after surgery to remove malignant tumors or tissue, flows a hyperthermic — or heated — sterilized chemotherapy solution through catheters directly into a patient’s abdominal cavity. The heat makes cancer cells “leak” so chemotherapy can enter the cells more effectively.
The effect of chemotherapy delivered directly to the abdomen is more potent than intravenous delivery, which takes longer to reach the intended area. And because the targeted delivery of HIPEC minimizes the rest of the body’s exposure to the treatment, it helps reduce some side effects, such as hair loss.
“Giving chemotherapy in the [operating room] is complicated, but it’s not something that can’t be done,” DeBernardo said. “We need to really show: Is this a beneficial therapy?”
Not only will the studies shed light on how well HIPEC controls when and where the cancer recurs, but they will also focus closely on side effects, costs and the length of hospital stays.
Here are the Phase 1 trials:
• A study involving the use of heated chemotherapy for ovarian cancer that has spread to the chest. What the surgical team has dubbed HITEC (the “T” coming from the word intrathoracic) is performed after minimally invasive lung surgery. “To my knowledge, no one has treated ovarian cancer [that has spread to] the chest like this,” DeBernardo said.
• A study for advanced ovarian-cancer patients whose cancer is in remission following surgery and chemotherapy. The patients will undergo HIPEC to prevent recurrence.
• A study for patients whose cancer recurs; HIPEC will be performed following surgery.
• A study for patients who undergo chemotherapy prior to surgery and HIPEC during the surgery.
Ovarian cancer is especially challenging to treat, as it is often not detected until it has spread. The cancer antigen 125 blood test, which can detect elevated levels of CA-125 — a trait often found in women with ovarian cancer — is not recommended as a screening test in women with an average risk of the disease because elevated levels can signal many other conditions.
Over the past two decades, treatments have evolved and improved, says DeBernardo.
Not only has it become easier to perform aggressive tissue-removing surgery (the primary way to diagnose ovarian cancer), but surgeons have become more specialized in cancer-tissue removal. Women also are able to better tolerate treatment.
“The thing about women with ovarian cancer [is,] we don’t cure very many people with ovarian cancer,” DeBernardo said. “We can control it, we can keep it at bay. But it almost always comes back. That’s where HIPEC comes in. It may improve things.”
The Cleveland Clinic began treating abdominal cancers — appendix, colorectal, gastric, ovarian and peritoneal mesolthelioma (a cancer of the lining of the abdominal cavity) with HIPEC in 2010. UH followed suit last summer, with DeBernardo working with other surgical oncologists and general surgeons to launch the program at UH Seidman Cancer Center.
Buoyed by the results of a national study that appeared in 2006 in the New England Journal of Medicine that showed a higher rate of survival for women with ovarian cancer who were treated with HIPEC versus intravenous chemotherapy, hospitals began to explore the HIPEC option.
“The unfortunate fact is, even though it’s good science, there is still only a minority of women getting offered that treatment,” DeBernardo said. The reasons are varied, and include that not all women have ready access to a hospital with a gynecologic on-
cologist or other skilled staff who are able to integrate HIPEC as part of treatment.
Last August, led by DeBernardo, UH launched a dedicated HIPEC program for gynecological cancers. The surgical team performed its first HIPEC treatment in August 2011. Since then, there have been more than two dozen cases.
Jan Belleville of Hubbard was DeBernardo’s first HIPEC patient.
Other than feeling something — not pain, but something — in her lower abdomen in the summer of 2006, Belleville had no reason to think it was ovarian cancer.
“I had had fibroids and thought that was all it was,” said Belleville, 68. But it wasn’t.
Belleville was diagnosed with Stage 4 ovarian cancer, which by then had spread through her abdominal cavity to her liver. Her first surgery included radiation therapy. Chemotherapy followed.
After being in remission for a year, Belleville’s cancer returned to her liver. She had another operation, followed by more chemotherapy and radiation. The cancer went into remission for six months, then came back. After more chemotherapy, remission again for three months. But the cancer came back again. This time it had spread to her lungs.
After treating Belleville with different types of chemotherapy that proved ineffective, DeBernardo and his colleague, Dr. Jason Robke, decided to do something else.
Last summer, they approached her about having HIPEC/HITEC surgery. She would be their first case.
“I never have doubted that I was being guided in the right direction,” Belleville said.
In late July, she had the first of two HIPEC/HITEC operations, on the left side of her chest. Four weeks later, surgeons operated on the right side. Those surgeries — which were each roughly three hours long, including about 90 minutes for administering the chemotherapy — were the seventh and eighth since she was first diagnosed.
The surgeries stabilized Belleville’s levels of CA-125, the protein in the blood that is found in ovarian cancer cells at a much higher level than in normal cells.
Shortness of breath and lack of energy earlier this month prompted more tests; X-rays detected spots on her lungs, evidence that the cancer had returned there.
Despite the news, Belleville and her husband went ahead with a planned vacation to Florida. Last week, she started intravenous chemotherapy.
“I think it bought me a really nice Thanksgiving, a beautiful holiday over Christmas,” an upbeat Belleville said about the six-month remission that followed her HIPEC/HITEC procedure. “I don’t consider this [recurrence] a setback.”
Key discovery in the treatment of ovarian cancer February 26, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: carcinogenesis, discovery, OGFr, opioidgrowth factor receptor, ovarian cancer, peptide-receptor, treatment
add a comment
Key discovery in the treatment of ovarian cancer
There is a great achievement in the study of ovarian cancer. Researchers have identified a peptide-receptor system, which will help in the understanding the progression and treatment of human ovarian cancer that affects a large population of women worldwide.
For this, researcher conducted this study on immunocompromised mice. They transplanted molecularly engineered humanovarian cancer cells to have a lower expression of opioidgrowth factor receptor (OGFr). They found that ovarian tumours grew rapidly.
These findings were made by the researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania. Their study brings a fresh insight into the pathogenesis and therapy of a lethal cancer that is the fifth most important cause of cancer-related deaths among women in the USA for over 75 years.
The opioid growth factor (OGF)(also-termed [Met5]-enkephalin)-OGFr axis plays a vital role in cancer as it is related to development, and cellular renewal by regulating cell proliferation. This study has also answered the requirement of this peptide-receptor system for the development of carcinogenesis.
The study has also found that Human ovarian cancer call lines that were genetically engineered to underexpress OGFr developed far more faster in tissue culture than control (empty vector/wildtype) cell lines.
Moreover, adding OGF to cultures of these genetically engineered cells did not respond to the inhibitory peptide and change cell number that showed the loss of OGFr interfered with the function of the OGF-OGFr axis with respect to controlling cell proliferation.
Immunocompromised mice in which ovarian cancer cells were transplanted that showed a reduction in OGFr exhibited tumours much earlier than controls, and these tumours developed more rapidly than controls.
With this knowledge that the pathway for OGF-OGFr regulation of cell proliferation in ovarian cancer is by way of escalating the cyclin-dependent inhibitory kinase proteins p16 and p21, it can be said that reducing the quantity of OGFr results in a rise in the number of cells entering the G1/S phase of the cell cycle.
This process has influence on increasing the progression of tumorigenic events.
These results reflects on the critical nature of OGFr in human ovarian cancer, and that the receptor along with its ligand, OGF, is necessary for deciding the course of these neoplasias.
Dr. Ian S. Zagon and Dr. Patricia J. McLaughlin found that endogenous opioids acts as growth factors, and have been pioneers in translating their findings from the bench to the bedside.
“Ovarian cancers frequently have a methylation of p16 that is associated with an increased progression of ovarian cancer and a loss of OGFr in ovarian tumors,” Dr. Renee N. Donahue a researcher in the Department of Neural and Behavioral Sciences said.
“The diminished expression of OGFr and its repercussions on tumorigenesis, only adds to the concern about the need for information concerning genetic and epigenetic changes that may impact the course of disease and its treatment.
“Our findings also hold potentially ominous overtones for those individuals taking naltrexone for addictive disorders. The dosage used for treatment of addiction blocks opioid receptors continually. The present findings that diminishing the OGF-OGFr axis by depleting the receptor exacerbates tumorigenesis, could place these patients using naltrexone at risk for accelerating disease processes that involve cell proliferation,” Dr. Donahue has been quoted as saying.
Dr. Steven R. Goodman, Editor-in-Chief of ExperimentalBiology and Medicine, opined that this forceful evidence confirmed the absolute requirement for OGFr (and OGF) as a tonically active inhibitory regulatory mechanism in ovarian cancer.
“As a corollary, amplifying the OGF-OGFr pathway is a novel and highly effective biotherapeutic strategy to suppress the progression of these deadly cancers,” Dr Goodman stated.
Experimental Biology and Medicine has published this study.
With inputs from ANI
Mother With Ovarian Cancer Fights To Give Back February 26, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: OMGI Cancer Sumiit, ovarian cancer, young adults
add a comment
Mother With Ovarian Cancer Fights To Give Back
MT. LEBANON (KDKA) – A young mother diagnosed with cancer has found a way to give back, by raising $6,000 to donate to a foundation that is helping to keep her alive.
Christina Radzilowicz, 42, of Mt. Lebanon thought that she had done everything right to live a healthy life. She was a runner, ate well and had regular medical check-ups. But none of that prevented her from becoming one of the 70,000 Americans between the ages of 15-and-39 diagnosed each year with cancer.
Three-and-a-half-years ago, her world was turned upside down when she found out she had Ovarian Cancer.
Her son, John, and daughter, Anastasya, were 10 and 6 at the time.
“I can’t let that be the case. Little kids are not projects you can wrap up in a couple of months,” Radzilowicz said.
She decided she needed to stay on this earth for her husband and children.
“I have this obligation that I willingly take to be their mom, and that includes fighting as hard as I can to allow that privilege.”
She found the I’m Too Young To Have Cancer Foundation online, and after listening to their webcasts she found reason for hope.
Radzilowicz has now set a new goal to raise $6,000 and donate it to this foundation. She has raised a quarter of it so far.
She is determined to be at the OMG! Cancer Summit For Young Adults in Las Vegas on March 30, where cancer patients can learn about education, advocacy, research and networking.
Radzilowicz knows that as a wife, mother and woman she has much to share with other young moms about living in the crucible of cancer.
“Yes, cancer may be a part of our lives but we’re going to get busy living,” she said.
If you’re willing to help Christina – donations can be made through her website, CrowdRise.com/CRad or through Eden’s Market, 99 Alfred Street, Mt. Lebanon, PA 15228 – and you can reach Christina directly firstname.lastname@example.org.
National Foundation for Cancer Research Funds Novel Approach to Early Detection of Ovarian Cancer February 26, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: cancer research, early detection, ovarian cancer, research grant
add a comment
National Foundation for Cancer Research Funds Novel Approach to Early Detection of Ovarian Cancer
Feb 23, 2012
LBUQUERQUE, N.M., Feb 23, 2012 (BUSINESS WIRE) — The National Foundation for Cancer Research has awarded a grant to Dr. Robert C. Bast, Jr. of The University of Texas MD Anderson Cancer Center to work with Senior Scientific LLC, a company owned by Manhattan Scientifics MHTX 0.00% , to apply Senior Scientifics’ technology to the early detection of ovarian cancer.
Senior Scientific has pioneered a novel technology using special magnetic sensors and magnetic nanoparticles for a highly sensitive and very specific approach to cancer detection.
The new grant, entitled “SQUID Imaging for Detection of Early Stage Ovarian Cancer,” will augment Dr. Bast’s ongoing program at The University of Texas MD Anderson Cancer Center with this emerging technology. Dr. Bast is a world leader in the early detection of ovarian cancer and was responsible for the discovery of the most accurate marker for this disease, CA-125.
The principal challenge in this grant is to overcome the problem of early detection of ovarian cancer where only 25% of ovarian cancer patients are currently detected in stage I. When the disease can be detected in Stage 1, 90% of those patients can be cured.
V. Gerald Grafe, president of Senior Scientific, said, “We are delighted with this support from the National Foundation for Cancer Research for our cooperation with Dr. Bast and The University of Texas MD Anderson Cancer Center. The focus of the grant is to combine Senior Scientifics’ highly sensitive technology, developed by our founder, Edward R. Flynn, PhD, with the expertise in cancer-markers developed at The University of Texas MD Anderson Cancer Center by Dr. Bast. Success of the program will allow us to detect ovarian cancer much earlier, leading to life-saving treatment for ovarian cancer patients.”
Dr. Flynn’s research was initially funded by the NIH, with the initial objective to be able to spot cancerous breast tumors years earlier than a mammogram can, with no radiation and high specificity and has now been applied to ovarian cancer. Dr. Flynn’s technology uses microscopic iron oxide nanoparticles, attached to known breast cancer antibodies, which specifically bind to breast cancers. The bound nanoparticles create a magnetic signal that is detected by an ultra sensitive magnetic sensor device developed by Dr. Flynn; this patented technology enables the technician to see the cancer with as few as 100,000 cells. A mammogram typically cannot detect a tumor until at least 100 million cells are present.
The new Ovarian Cancer grant triggers collaboration between Drs. Bast, Flynn & a team led by Richard S. Larson, MD, PhD, Vice Chancellor UNM Health Sciences Center in New Mexico.
About Manhattan Scientifics
Manhattan Scientifics Inc. ( http://www.mhtx.com ) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
SOURCE: Manhattan Scientifics, Inc.
Endometriosis increases ovarian cancer risk February 26, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, uterine cancer, vaginal cancer.
Tags: endometriosis, ovarian cancer, screening test
add a comment
Endometriosis increases ovarian cancer risk
By Stephen Adams
Thursday February 23 2012
Celeste Leigh Pearce from the University of Southern California, Los Angeles, lead author of the study, said the “breakthrough” could lead to screening programmes or risk-reduction surgery for higher-risk women.
She and her team found that endometriosis tripled a woman’s lifetime risk of developing a type called clear cell ovarian cancer, from 1 in 500 to one in 180.
It also more than doubled the risk of two other types, called endometrioid and low-grade serous ovarian cancer, from one in 400 to one in 180.
The US researchers made their conclusions in The Lancet Oncology after looking at data from over 23,000 women, of whom almost 8,000 had invasive ovarian cancer.
Dr Paul Pharoah from Cambridge University said it was “well established” that having endometriosis increased a woman’s lifetime risk of all types of ovarian cancer from about one in 50 to one in 40.
Prof Hani Gabra, director of the Ovarian Cancer Action Research Centre at Imperial College London, described the study as “interesting”.
“However, most women with endometriosis will not go on to develop ovarian cancer,” he added.
“It is important that all women should be aware of the signs and symptoms of ovarian cancer and consult their GP if they are concerned.”
About 10 per cent of women are thought to develop endometriosis, where womb lining tissue develops outside the uterus, although estimates vary. It can cause painful periods, while sex can hurt, and it can reduce fertility too.
– Stephen Adams
Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer. February 24, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: abdomen, ablative surgery, cancer detection, CT scan, cytoreductive surgery, MRI, ovarian cancer, pelvis, peritoneal implants, pet scan, recurrence
add a comment
Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Departments of aNuclear Medicine bRadiology cObstetrics and Gynecology dBiostatistics and Medical Informatics ePathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
The aim of this study was to evaluate the diagnostic value of 2-(fluorine-18)-fluoro-2-deoxy-D-glucose (F-FDG) PET/CT in comparison with MRI for the detection of recurrent ovarian cancer.
Forty-seven patients with suspected ovarian cancer recurrence after total ablative or cytoreductive surgery, as well as neoadjuvant or adjuvant chemotherapy, who had undergone F-FDG PET/CT imaging were recruited for the present study. All patients also underwent MRI within a month of F-FDG PET/CT for the same purpose. Recurrent cancer in the abdomen and pelvis was evaluated in each of the 47 patients and classified as either distant metastasis or local pelvic recurrence involving the vaginal stump, peritoneal implants, supradiaphragmatic region, and/or abdominal and pelvic lymph nodes. Special attention was paid to peritoneal implants. These were divided into five groups according to size of the implants: less than 0.5 cm (group 1), 0.5-1 cm (group 2), 1-2 cm (group 3), 2-3 cm (group 4), and larger than 3 cm (group 5). PET/CT findings were compared with abdominopelvic MR findings. Statistical analysis was carried out using the Wilcoxon signed rank test.
Thirty-nine of 47 patients were found to have recurrent ovarian cancer. Both PET/CT and MRI were negative for recurrence in six patients. Overall sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of PET/CT were 97.5, 100, 100, 87.5, and 97.8%, respectively, whereas those of MRI were 95, 85.7, 97.4, 75, and 93.6%, respectively. For the peritoneal implants in groups 2 and 3, the sensitivity, negative predictive value, and diagnostic accuracy values of PET/CT were significantly better than those of MRI (P<0.05).
The present study revealed that PET/CT is similar to conventional MRI for the detection of recurrent ovarian cancer. PET/CT has greater accuracy in the detection of small-to-medium-sized (<2 cm) peritoneal implants compared with MRI. This may affect surgical decision making.
Epigenetics in ovarian cancer. February 24, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer.
Tags: advanced-stage disease, CpG island methylation, epigenetics, gynecological cancer, histone modification, ovarian cancer
add a comment
Epigenetics in ovarian cancer.
Department of Reproductive Medicine and Gynaecology, Gynaecological Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Ovarian cancer is the most lethal gynecological cancer. Due to few early symptoms and a lack of early detection strategies, most patients are diagnosed with advanced-stage disease. Most of these patients, although initially responsive, eventually develop drug resistance. In this chapter, epigenetic changes in ovarian cancer are described. Various epigenetic changes including CpG island methylation and histone modification have been identified in ovarian cancer. These aberrations are associated with distinct disease subtypes and present in circulating serum of ovarian cancer patients. Several epigenetic changes have shown promise for their diagnostic, prognostic, and predictive capacity but still need further validation.In contrast to DNA mutations and deletions, epigenetic modifications are potentially reversible by epigenetic therapies. Promising preclinical studies show epigenetic drugs to enhance gene re-expression and drug sensitivity in ovarian cancercell lines and animal models.
Ovarian Cancer Research Resources, and Clinical Trials February 18, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: clinical trials, ovarian cancer resources, research information
add a comment
Ovarian Cancer Research Resources, and Clinical Trials
Inclusion on the list does not constitute an endorsement of any clinical trial, or treatment method. Information only. Please check out any resource that may be listed.
As a matter of policy, the Ovarian Cancer National Alliance does not endorse any individual clinical trial or treatment.
ACRIN: American College of Radiology Image Network
Clinical Trials and Insurance Coverage: A Resource Guide
Information on insurance coverage for clinical trials from the National Cancer Institute.
Clinical Trials: Questions and Answers
National Cancer Institute fact sheet on clinical trials from 2006.
Clinical Trials: What You Need to Know
Information on cancer clinical trials, including results of research that The Coalition of National Cancer Cooperative Groups conducted with cancer patients who have participated in clinical trials.
Learning About Clinical Trials
Fact sheets and brochures on clinical trials from The National Cancer Institute that can be downloaded in PDF format. (The section on patient care costs is particularly helpful.)
10 Step Guide to Finding a Cancer Treatment Clinical Trial
Participating in a Trial: Questions to Ask Your Doctor
Lists sample questions related to clinical trials ranging from questions specific to study design to questions associated with insurance costs. Provides a good starting point for women who want to put together a list of questions to ask their doctors.
The Women’s Cancer Network—Clinical Trials
Information on how clinical trials work and about specific clinical trials for gynecologic cancers.
American Association for Cancer Research
Information about research and links to publications and databases.
American Institute for Cancer Research
Educates the public about the results of research on diet and cancer prevention.
American Society of Clinical Oncology
Database of cancer research abstracts and current news on cancer research.
British Medical Journal
Original scientific studies, review and educational articles, and papers commenting on the clinical, scientific, social, political, and economic factors affecting health.
Hereditary Cancer Institute
Research and educational information about hereditary cancer as well as information on genetic testing and links of interest to those affected by cancer.
Journal of American Medical Association
An international peer-reviewed general medical journal promoting the science and art of medicine and the betterment of the public health.
Journal of Clinical Oncology
Original research and reviews about women’s cancers, supportive care and quality of life issues, prevention, and pharmacology.
Journal of Gynecologic Oncology
Access to articles about research in gynecologic oncology.
National Center of Competence in Research Molecular Oncology
Information about cancer research, comprehensive glossary, and links for further reading.
Ovarian Cancer Research Directory
Ovarian Cancer Research Fund
Links to resources as well as information about fundraising events (primarily in New York).
Ovarian Cancer Research Program
Information from the Department of Defense about the Congressional appropriations and funding for the Ovarian Cancer Research Program.
Research for Ovarian Cancer and Continued Survival (ROCCS)
Offers education and public awareness about ovarian cancer.
Ovarian Cancer Specialized Programs of Research Excellence (SPOREs)
Information about National Cancer Institute funded programs that focus on interdisciplinary cancer research with an exchange between specialists in laboratories and clinical settings.
The Lancet Interactive Medical Journal
An independent journal without affiliation to a medical or scientific organization that publishes high-quality clinical trials.
The Ovarian Cancer Institute
Information about ovarian cancer research, news, and events.
Tags: internet support groups, online resources, ovarian cancer, treatment resources
add a comment
Ovarian Cancer Treatment Resources
Inclusion in the list does not constitute an endorsement of any individual, provider, hospital or medical facility
Dana-Farber Cancer Institute—Ovarian Cancer
Information about treatment, clinical trials, screening, and prevention.
Learn more about nuclear medicine and the use of molecular imaging for cancer patients.
Get Palliative Care
Provides information about palliative care, which focuses on relieving pain, stress, and other symptoms of serious illness.
M.D. Anderson Cancer Center
Provides information about integrated programs in cancer treatment, clinical trials, education programs and cancer prevention.
Memorial Sloan-Kettering Cancer Center
Provides information about treatment for ovarian cancer in addition to research and support for cancer patients and researchers.
National Comprehensive Cancer Network
Clinical recommendations and information about events and resources.
National Lymphedema Network
Education and guidance for lymphedema patients, health care professionals and the general public on primary and secondary lymphedema.
Radiation Therapy Answers
Information about radiation therapy from physician members of the American Society for Therapeutic Radiology and Oncology. Help finding a radiation oncologist.
RxList—The Internet Drug Index
Provides information about prescription drugs to consumers and health care professionals.
Understanding the Approval Process for New Cancer Treatments
Information on the role of the FDA in the approval process for new cancer treatments.
Internet support groups (listservs or chat rooms) are free email or chat room discussions on specific topics of interest. Email subscribers receive copies of emails sent by any members of the group to the listserv. Some active groups generate dozens of messages a day. If you subscribe to the “digest” mode, you will receive one email containing all of the messages posted that day. Email discussion groups are an excellent way to connect with people in similar circumstances.
Chat rooms can be either “live” chats or bulletin board-type chats. A live chat is similar to walking into a room where a discussion is already taking place except you will be typing your messages. In a bulletin board-type chat room, a participant may post a message, and others will usually respond right below that message. With any of these support groups, you may elect to participate or just observe by reading the messages of others and the responses that their messages generate.
ACOR (Association of Cancer Online Resources) hosts dozens of cancer email discussion groups. Discussion groups hosted by ACOR include OVARIAN–an unmoderated discussion list with over 1,000 subscribers. ACOR also has discussion groups on CANCER, CANCER-FATIGUE, CANCER-PAIN, CANCER-PARENTS, and dozens of others. ACOR offers a convenient automatic subscription feature for discussion mailing lists at http://www.acor.org. Click on mailing lists (on the left nav bar) then click on the group you are interested in joining.
The National Ovarian Cancer Coalition (NOCC) hosts a chat area for women with ovarian cancer. To participate, go to www.ovarian.org/ and click on “Chat” listed under “Support” on the left nav bar. They have a feature that allows participants to schedule chat events on particular topics. The NOCC also hosts multiple listservs on various topics including a resource list, awareness list, caregiver’s list, humor list, and others. To subscribe, click on “Mailing lists” under “Support” on the left nav bar.
OncoLink, at the University of Pennsylvania, has an online FAQ (document answering frequently asked questions) about cancer listservs athttp://oncolink.org/resources/faq/listserv.html. If you would like to learn a bit more about them and get answers to some specific questions, this is a good place to start.
Steve Dunn, a cancer survivor, clearly explains cancer types and staging, chemotherapy, pathology reports, and the pros and cons of researching your own cancer. He recommends books, includes inspirational patient stories, and has links to many of the best cancer sites on the Web. CancerNet
An NCI sponsored comprehensive source of cancer information including types of cancer, treatment options, clinical trials, genetics, coping, support, resources, and cancer literature. CancerNet is one of the most comprehensive information sources for cancer patients on the Net. CanSearch: Online Guide to Cancer Resources
Service of the National Coalition for Cancer Survivorship that leads you step-by-step through an online search.
- Clinical Trials
A consumer-friendly database sponsored by the National Institutes of Health that provides information on more than 4,000 federal and private medical studies involving patients at more than 47,000 locations nationwide. Conversations
International newsletter for women fighting ovarian cancer. Gilda Radner Familial Ovarian Cancer Registry
Roswell Park Cancer Institute hosts an international registry of families with two or more members with ovarian cancer. They promote ovarian cancer research and offer a help line, education, and peer support for women with a high risk of ovarian cancer. OncoLink
University of Pennsylvania cancer specialists founded OncoLink in 1994 to help cancer patients, families, healthcare professionals, and the general public get accurate cancer-related information at no charge. It contains information on ovarian cancer, causes, treatment options, hormones, symptom management, causes, psychosocial support and personal experiences. PubMed
The National Library of Medicine’s free search service provides access to the 9 million citations in MEDLINE (with links to participating on-line journals) and other related databases. Also includes FAQs, news, and clinical alerts. Ovarian Cancer Research Notebook
The OCRN is a comprehensive list of articles on treatment for ovarian cancer that contains approximately 3,000 documents. It is maintained and upgraded by the National Ovarian Cancer Association of Toronto, Canada.The Women’s Cancer Networkwww.wcn.org
- Site developed by the Society of Gynecologic Oncologists to help prevent, detect, and conquer cancer in women. It has cancer information, a bookstore, survivor stories, links to other web sites, and a helpful find-a-doc feature.